As we begin a new decade, having built this strong base business, transitioned our pipeline to address larger rare indications, laid the foundation for significant profitability with valrox and vosoritide approvals, we have a diversified risk and positioned ourselves for substantial success in both the near-term and the long-term.-------------------------------------------------------------------------------- Henry J. Fuchs, BioMarin Pharmaceutical Inc. - President of Worldwide Research & Development [8] -------------------------------------------------------------------------------- Other than we'll do a postapproval registry if that's required from a regulatory perspective, although obviously, documenting the long-term outcomes for patients treated with valrox is going to be of prime interest to the medical community over time.